Meeder Asset Management Inc. Buys Shares of 16,909 Replimune Group, Inc. (NASDAQ:REPL)

Meeder Asset Management Inc. bought a new position in Replimune Group, Inc. (NASDAQ:REPL) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,909 shares of the company’s stock, valued at approximately $205,000.

A number of other hedge funds also recently made changes to their positions in the stock. Erste Asset Management GmbH bought a new position in Replimune Group in the 3rd quarter valued at approximately $133,000. Sei Investments Co. bought a new position in shares of Replimune Group in the 4th quarter valued at $148,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Replimune Group during the 4th quarter valued at $150,000. Arizona State Retirement System bought a new stake in Replimune Group during the 4th quarter worth $156,000. Finally, BNP Paribas Financial Markets increased its holdings in Replimune Group by 81.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after purchasing an additional 6,748 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. JPMorgan Chase & Co. lifted their price target on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. HC Wainwright raised their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. BMO Capital Markets lifted their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Jefferies Financial Group upped their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Trading Down 6.2 %

Shares of REPL stock opened at $9.75 on Tuesday. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The stock has a 50 day simple moving average of $12.67 and a two-hundred day simple moving average of $12.16. The company has a market cap of $750.90 million, a P/E ratio of -3.18 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Research analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.